CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled
Drug / intervention
Panobinostat/LBH589drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00880269
NCT00880269Phase 2Completed
CompareCT.gov

A Phase II Study of Oral Single Agent Panobinostat in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Novartis Pharmaceuticals·interventional·Posted Apr 13, 2009·Updated Feb 23, 2017

In Brief

A Phase 2 clinical trial evaluating Panobinostat/LBH589 for Refractory Leukemia and Acute Myelogenous Leukemia. Completed, enrolled 59 participants across 40 sites in 12 countries.

Detailed Summary

This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Leukemia, Acute Myelogenous Leukemia
CountriesAustralia, Belgium, France, Germany, Italy, Peru, South Korea, Spain, Switzerland, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 13, 2009
Enrollment StartAug 1, 2009
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.2 years ago

Interventions

Panobinostat/LBH589drug